AI
| Followers | 842 |
| Posts | 122793 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Sunday, October 11, 2009 8:33:58 AM
Nucleoside vs Nucleotide: Why Does It Matter?
[Updated for VRUS’ PSI-879/PSI-938; clarified that new-generation
nucleotide prodrugs resolve to the monophosphate nucleotide.]
A nucleotide (right) consists of a nucleoside (left) and 1-3 attached
phosphate groups. The nucleotide depicted below right is a monophosphate.
Why does the distinction between a nucleoside and a nucleotide matter?
The active agent for all nucleoside/nucleotide antiviral drugs is the triphosphate nucleotide, which is three phosphorylation steps removed from the nucleoside.
IDIX found that a major reason for the failure of NM283, a first-generation nucleoside, was the in vivo inefficiency and patient-to-patient variability of the first phosphorylation step, which converts a nucleoside into a monophosphate nucleotide.
IDIX’s IDX184 and VRUS’ PSI-7851, PSI-879, and PSI-938 are prodrugs of the monophosphate nucleotide; these drugs thus sidestep the problem encountered with NM283 by performing the first phosphorylation step ex vivo.
(The new-generation drugs mentioned above perform the second and third phosphorylation steps in vivo, but these steps do not present a practical problem because they are more efficient and less prone to variability than in vivo performance of the first phosphorylation step.)
[Updated for VRUS’ PSI-879/PSI-938; clarified that new-generation
nucleotide prodrugs resolve to the monophosphate nucleotide.]
A nucleotide (right) consists of a nucleoside (left) and 1-3 attached
phosphate groups. The nucleotide depicted below right is a monophosphate.
Why does the distinction between a nucleoside and a nucleotide matter?
The active agent for all nucleoside/nucleotide antiviral drugs is the triphosphate nucleotide, which is three phosphorylation steps removed from the nucleoside.
IDIX found that a major reason for the failure of NM283, a first-generation nucleoside, was the in vivo inefficiency and patient-to-patient variability of the first phosphorylation step, which converts a nucleoside into a monophosphate nucleotide.
IDIX’s IDX184 and VRUS’ PSI-7851, PSI-879, and PSI-938 are prodrugs of the monophosphate nucleotide; these drugs thus sidestep the problem encountered with NM283 by performing the first phosphorylation step ex vivo.
(The new-generation drugs mentioned above perform the second and third phosphorylation steps in vivo, but these steps do not present a practical problem because they are more efficient and less prone to variability than in vivo performance of the first phosphorylation step.)
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
